Related Experiment Videos
Systemic amyloidosis of beta 2 microglobulin type.
K Mazanec1, J McClure, C J Bartley
1Department of Pathological Sciences, University of Manchester.
Journal of Clinical Pathology
|September 1, 1992
Summary
Long-term hemodialysis patients can develop beta 2 microglobulin amyloidosis. This condition involves amyloid deposits in various tissues, including the heart, joints, and even the brain.
Area of Science:
- Nephrology
- Pathology
- Rheumatology
Background:
- Chronic kidney disease patients often require long-term hemodialysis.
- Beta 2 microglobulin (B2M) is a protein that can accumulate in patients with impaired kidney function.
- Amyloidosis is a condition characterized by the buildup of abnormal proteins in organs and tissues.
Observation:
- A patient on hemodialysis for 15 years presented with systemic amyloidosis.
- Amyloid deposits were notably found in the myocardium, intervertebral discs, joint cartilages, and tendons.
- Smaller deposits were observed in blood vessels of the lungs, liver, adrenal glands, and brain, as well as in the prostate, testis, and kidney.
Findings:
- The patient's condition was diagnosed as beta 2 microglobulin amyloidosis.
- Histopathological examination revealed significant amyloid deposition in multiple organ systems.
- Calcification foci were present in some amyloid deposit sites, particularly in the kidney.
Implications:
- This case highlights the potential for significant systemic complications in long-term hemodialysis patients.
- Understanding the distribution of B2M amyloidosis is crucial for patient management and monitoring.
- Further research may explore preventative strategies or targeted therapies for dialysis-related amyloidosis.